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The transcription factors T-bet and GATA3 are
important reciprocal determinants of Th1 and Th2 T
helper cell differentiation. Recent evidence suggests
that these factors may affect airway immunopathol-
ogy in asthma.
Asthma remains one of the commonest chronic
inflammatory diseases and has a major impact on the
life of sufferers. It is associated with allergy mediated
by IgE antibodies, eosinophilic airway inflammation
and remodelling including collagen deposition
beneath the epithelial basement membrane, mucus
secretion and increased airway smooth muscle.
These changes are thought to contribute to both the
episodic airway narrowing that defines the condition
and to airway hyperresponsiveness — an increased
tendency to narrow the airways to irritant stimuli [1].
T helper cells are divided into subsets: Th1, produc-
ing predominantly interferon γ (IFNγ), and Th2 pro-
ducing interleukin-4 (IL-4) and IL-5 but not IFNγ. IL-4
switches B cells towards IgE synthesis and IL-5 is 
an eosinophil survival and development factor [1,2].
Evidence is accumulating to support the view that 
the interplay between these T helper cell subsets 
is important in asthma. Recent studies have shown
that Th2-type cytokines are produced by airway
T cells in human asthma, and that allergen-reactive
Th2 cells can be isolated from the airway of allergic
asthmatics [1].
Th1 and Th2 cells develop from naïve T cells during
an immune response, and largely determine the nature
of that response through the profile of cytokines they
secrete. This process involves a complex pattern of
interacting cytokines, transcription factors and sig-
nalling pathways [2]. Szabo et al. [3] defined one such
transcription factor which they termed T-bet (T box
expressed in T cells) which not only induced an IFNγ-
producing Th1 phenotype, but also repressed IL-4 
and IL-5 production from differentiated Th2 cells. 
In a recent paper [4], these workers go on to show 
evidence for decreased numbers of CD4+ T cells
expressing T-bet in the airway of human asthma
patients relative to control subjects. Moreover, dele-
tion of the T-bet gene in mice resulted in airway
eosinophilia, Th2 cytokine production, airway hyper-
responsiveness and changes of airway remodelling in
the absence of allergen sensitisation and inhaled chal-
lenge [4]. How do these findings relate to other 
published work in terms of Th1 and Th2 development
and how are they relevant to our understanding of
asthma?
Differentiation of Th1 and Th2 Cells
The major determinant of whether an activated naïve
CD4+ T helper cell develops into a Th1 or Th2 effec-
tor/memory cell is the presence of IL-12 or IL-4,
respectively. In addition, IFNγ and IL-18 can potentiate
Th1 development. The molecular events that pro-
gramme the Th1 or Th2 phenotype have been exten-
sively studied in vitro and by gene deletion in mice [2].
Immediately after T cell receptor activation, naïve T
cells can transcribe messenger RNA for both IFNγ and
IL-4 [5], but cytokines or other signals are required to
direct Th1 or Th2 polarisation. IL-12 acts through
signal transducer and activator of transcription 4
(Stat4) to increase IFNγ production [2]. IFNγ (IFNα in
human T cells) maintains expression of the IL-12 β2
receptor chain (IL-12Rβ2), whereas IL-4 activates
Stat6 to downregulate IL-12Rβ2 [2]. Deletion of the
Stat4 or Stat6 genes results in in vivo deficiency of
Th1 or Th2 responses, respectively, but the precise
interaction of these STAT proteins with other tran-
scription factors and cytokine gene promoters
remains uncertain. Transcription factors interacting
with the IL-4 promoter have been shown to be
expressed in Th2 cells but not Th1 cells, including
c-Maf, NIP45 and JunB, all of which  increase IL-4
gene activation, as does NFATc. Gene deletion or
overexpression of these factors correspondingly
affects IL-4 production [6]. Th2 differentiation involves
chromatin remodelling to allow access of these
factors to the IL-4 promoter.
GATA3 and T-bet
Recently, two transcription factors have been defined
that can control Th1 or Th2 differentiation and override
previously programmed cytokine patterns. GATA3 is
expressed in Th2 cells but not Th1 cells, and trans-
genic mice overexpressing GATA3 produced Th2
cytokines even when cultured in Th1-polarising condi-
tions in the absence of IL-4 [6]. Retroviral transfer of
GATA3 into Th1 cells could reduce IFNγ production
and induce IL-4 and IL-5 [7,8]. Thus not only can
GATA3 induce Th2 cytokines, but it can also repress
Th1 cytokine production. 
T-bet has been suggested to act in a similar fashion
for Th1 cells. T-bet was rapidly induced in naïve CD4+
T cells cultured in Th1-polarising conditions (in the
presence of IL-12 and anti-IL-4 antibodies), and trans-
activated a reporter gene driven by the IFNγ promoter.
T-bet expression is restricted to Th1 and not Th2 cells
[3]. Retroviral gene transfer of T-bet could make Th2
cells activate IFNγ production and repress IL-4 and IL-5.
T-bet also induced other Th1 phenotypic changes in
developing Th2 cells: expression of the CCR5
chemokine receptor and upregulation of the P-selectin
ligand PGSL-1. Furthermore, repression of Th2
cytokines (and IL-2) was not IFNγ dependent as it
occurred even in T cells deficient in the IFNγ receptor.
How T-bet reduces IL-4 and IL-5 expression remains
unclear, as it did not affect expression of a reporter
gene driven by the IL-4 promoter [3].
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Although it was suggested that T-bet expression
may be stochastic [9], it has recently been shown that
T-bet is upregulated in lymphoid and myeloid cells by
IFNγ in a Stat1-dependent manner within 6 hours, and
this early T-bet activation is Stat4 independent [10].
However, Grogan et al. [5] showed that at 72 hours
T-bet upregulation in Th1 was not seen in Stat4-defi-
cient mice, though this could be an indirect effect via
IFNγ [6]. GATA3 expression can occur in the absence
of Stat6, but Stat6-dependent pathways upregulate
expression [7]. Taken together these data suggest 
that initial Th1 differentiation is dependent on IFNγ-
induced T-bet expression, whilst GATA3 will direct
Th2 differentiation. Full expression of a polarised
immune response may require expansion, selective
survival and stabilisation of cytokine mRNA of Th1
cells via IL-12-induced Stat4, with amplification of
IFNγ production by IL-18, or Th2 cells via IL-4-induced
Stat6 [2]. A key part of Th1 development is retention of
IL-12Rβ2 — and hence IL-12 responsiveness — whilst
Th2 cells lose IL-12Rβ2. T-bet was found to induce
IL-12Rβ2 expression [9], so that part of the phenotype
resulting from T-bet deficiency may result from a loss
of ability to retain IL-12 responsiveness. These control
elements are summarised in Figure 1. Whether the
same control mechanisms apply in human cells
remains to be fully confirmed.
GATA3 and T-bet in the Airway
How then do these Th1 and Th2 control factors act in
the asthmatic airway? Finotto et al. [4] found relatively
fewer T-bet-expressing CD4+ T cells in the airways of
asthmatics than control groups, which fits with previ-
ous findings that T cells in asthmatic subjects are
predominantly of a Th2 phenotype (which do not
express T-bet) [4]. These authors went on to show
that T-bet deficiency alone in mice could induce
airway changes similar to those seen after allergen
challenge of sensitised rodents.
Animals heterozygous for T-bet deficiency (T-bet+/–)
did not show any increase in IL-4, tumour necrosis
factor α or transforming growth factor β in the airways
compared with wild-type controls [4]. The heterozy-
gotes  did, however, show airway hyperresponsive-
ness, increased expression of IL-5 in the airway, and
airway remodelling without challenge, similar to that
seen in the homozygous deficient animals. In culture
CD4+ T cells from the heterozygous mice were not dif-
ferent from wild type in terms of Th2 cytokine produc-
tion in neutral conditions [11].
One interpretation of these finding in T-bet–/– mice
would be that Th2 cytokines may be basally repressed
by T-bet, and that absence of T-bet allows their
expression. Transgenic overexpression of GATA3 in T
cells led to cells with characteristics of a Th2 pheno-
type, so the balance of T-bet and GATA3 may deter-
mine the default T cell phenotype [12]. Another
possibility is that environmental antigens drive Th2
development in the absence of T-bet, because they
cannot induce IFNγ (and IL-12Rβ2) and thus Th1
development is deficient. It will be of interest to know
if T-bet–/– T cells are IL-12 responsive. Thus the
T-bet–/– findings suggest that Th1 cells and IFNγ pro-
duction may be a major regulator of basal Th2
responses. It has also been postulated that regulatory
cells producing IL-10 attenuate Th2 responses to
allergen. However, recent data suggest that these
IL-10-producing regulatory cells express neither T-bet
Figure 1. T-bet in Th1 and Th2 CD4+ T cell differentiation.
Naïve CD4+ T cells upregulate T-bet in response to IFNγ in a Stat1-dependent manner leading to upregulation of IFNγ production and
repression of Th2 cytokines, together with expression of IL-12Rβ2, hence IL-12 responsiveness. Increased IFNγ production and Th1
commitment occurs through IL-12 acting via Stat4 (which is not required for but may augment T-bet expression) and by IL-18. IL-4
downregulates IL-12Rβ2 and GATA3 increases Th2 cytokine expression (which is further enhanced by c-Maf, NIP45, JunB and NFATc)
and represses IFNγ production. Th2 cytokines are involved in B-cell switching to IgE production (IL-4 and IL-13), eosinophil infiltra-
tion (IL-5 and IL-9), and airway remodelling and mucus secretion (IL-13): all of which may contribute to airway hyperresponsiveness
and other features of asthma. The absence or relative deficiency of T-bet favours spontaneous airway features of asthma, in part
through favouring Th2 development.
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nor GATA3 [13], so these cells should still be active in
the absence of T-bet.
It would be of some interest to know whether the
Th2-mediated pathology in T-bet–/– mice is restricted
to the airway or whether there is ‘allergic’ inflamma-
tion at other sites. Sensitisation and inhaled ovalbumin
challenge failed to induce a further increase in airway
hyperresponsiveness in either T-bet–/– or T-bet+/– mice
(in this model inhaled allergen will induce airway
hyperresponsiveness in sensitised wild-type mice) [4].
It would also be of interest to know if specific IgE or
ovalbumin-specific T cells were induced in the lungs
after challenge. Since T-bet is expressed in non-lym-
phoid cells [10], it will be important to look for any
direct effects in other cell types such as airway
smooth muscle or epithelium.
Although overproduction of Th2 cytokines in the
airway, like T-bet deficiency, can induce an asthma
phenotype, it is of note that these changes can also
be seen after sensitisation and inhalation challenge in
mice deficient in IL-4, IL-5, both IL-4 and IL-5, or IL-9
[14,15]. Thus targeting a single (or several) Th2
cytokine in asthma may not be effective, and indeed
recent human trials of monoclonal antibodies blocking
IL-5 were disappointing although soluble IL-4 recep-
tor had some effect [16,17]. Although human airway
Th2 cells from asthmatics are still responsive to IL-12
in vitro [18], exogenous IL-12 had no effect on asthma
symptoms or lung function despite reducing blood
and sputum eosinophilia [19]. In animal models most
workers report that transfer of Th1 cells into the
airways can exacerbate Th2-mediated lung pathology,
and Th1 cells can themselves cause disease [20], so
switching on T-bet in asthma might not be beneficial.
The confirmation of T-bet and GATA3 as Th1 and
Th2 control factors in vitro and in vivo is of great inter-
est. Whether this will allow the therapeutic manipula-
tion of the immune response that has been a goal ever
since the description of the Th1/Th2 dichotomy is
uncertain, but these are tantalising targets.
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